As of March 1, 2018, Camelot is working toward filing a new S-1 Registration Statement in order to regain its fully reporting status and resume trading.
The company has not traded since July 23, 2013, when it was unable to complete its annual and quarterly filing requirements due to lack of funding.
Wiener Dog Nationals (2013) Pythagoras (2013) The Escape (2013) Privacy (2012) A Warrior's Heart (2011) Eliminate: Archie Cookson (2011) Skateland (2010) Fink!
(2010) The Understudy (2009) The Perfect Game (2009) Next of Kin (2008) Mothers and Daughters (2004) Scavengers (2012) Deliver Me to Hell (2012) Attack of the Herbals (2011) Never Sleep Again: The Elm Street Legacy (2010) Screwball: The Ted Whitfield Story (2009) About Face: The Story of the Jewish Refugee Soldiers of World War II (2011) Never Sleep Again (2010) From Silence to Sound (2007) The following unaudited financial information is subject to adjustment upon completion of the Company's annual audit and review of prior years.
These and other factors has created a heavy reporting burden on the Company, requiring management to spend excessive time and effort preparing and reviewing old information instead of focusing on business operations and requiring the Company to spend more money on outside counsel and auditors to help prepare the reports.
The trading halt was in connection with a public administrative hearing instituted by the Securities and Exchange Commission (”SEC”) because Camelot, a Delaware corporation located in Irvine, California with a class of securities registered with the Commission pursuant to Exchange Act Section 12(g), was delinquent in its periodic filings with the SEC, having not filed any periodic reports since it filed a Form 10 for the period ended September 30, 2010, which reported a net loss of $8,026,537 for the prior nine months.
As of July 18, 2013, the common stock of Camelot was quoted on OTC Link, had ten market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).